Results 11 to 20 of about 19,741 (164)

TILT Biotherapeutics [PDF]

Human Vaccines & Immunotherapeutics, 2017
Non peer ...
Akseli Hemminki
doaj   +4 more sources

Integrated BioTherapeutics [PDF]

Human Vaccines & Immunotherapeutics, 2018
M. Javad Aman
doaj   +3 more sources

Advances in the Development of Biotherapeutics [PDF]

BioMed Research International, 2015
Biotherapeutics are currently the fastest growing group of pharmaceuticals, being a treatment option for a variety of chronic and sometimes life-threatening conditions. They represent a diverse group of biological products that broadly encompasses nucleic acids, proteins, whole cells, viral particles, and vaccines.
Pedro H. Oliveira, Juergen Mairhofer, Paula M. Alves, Alvaro R. Lara, Cleo Kontoravdi   +4 more
openaire   +3 more sources

The Emerging Biotherapeutic Agent: Akkermansia [PDF]

Indian Journal of Microbiology, 2021
The human gastrointestinal tract (GIT) is a well-recognized hub of microbial activities. The microbiota harboring the mucus layer of the GIT act as a defense against noxious substances, and pathogens including Clostridium difficile, Enterococcus faecium, Escherichia coli, Salmonella Typhimurium.
Kalia, Vipin Chandra, Gong, Chunjie, Shanmugam, Ramasamy, Lin, Hui, Zhang, Liaoyuan, Lee, Jung-Kul   +5 more
openaire   +2 more sources

Immunogenicity of Biotherapeutics—An Overview [PDF]

Journal of Immunotoxicology, 2006
With the recent increase in the approval and use of biotherapeutics in clinical practice, management of the development of anti-drug antibodies (ADA) has become a key issue for effective long-term use of these drugs. In most instances, the clinical benefit derived from the use of the therapeutics outweighs the risk of developing ADA. In rare instances,
openaire   +2 more sources

Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors

CPT: Pharmacometrics & Systems Pharmacology
Fanastomig (also known as EMB‐02) is a bispecific antibody targeting programmed cell death protein‐1(PD‐1) and lymphocyte activation gene‐3 (LAG‐3), developed for the treatment of advanced solid tumors.
Chengjun Jiang, Fang Ren, Mingfei Zhang, Qiaoyang Lu, Shuqi Zeng, Guang Yang, Yonghong Zhu   +6 more
doaj   +1 more source

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1

Cells, 2021
Oncolytic viruses provide a biologically multi-faceted treatment option for patients who cannot be cured with currently available treatment options.
Riikka Havunen, Riikka Kalliokoski, Mikko Siurala, Suvi Sorsa, João M. Santos, Victor Cervera-Carrascon, Marjukka Anttila, Akseli Hemminki   +7 more
doaj   +1 more source

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells

mAbs, 2021
Biotherapeutics, which are biologic medications that are natural or bioengineered products of living cells, have revolutionized the treatment of many diseases.
Sivan Cohen, Srividya Myneni, Anna Batt, Joyce Guerrero, Jochen Brumm, Shan Chung   +5 more
doaj   +1 more source

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Scientific Reports, 2022
T-cell engagers (TCEs) are a growing class of biotherapeutics being investigated in the clinic for treatment of a variety of hematological and solid tumor indications.
Julie A. Zorn, Matthew L. Wheeler, Ralston M. Barnes, Jim Kaberna, Winse Morishige, Marek Harris, Richard Y.-C. Huang, Jack Lohre, Yu Ching Chang, Bryant Chau, Kathleen Powers, Ian Schindler, Naveen Neradugomma, Winston Thomas, Xiaoyun Liao, Yinhan Zhou, Sean M. West, Feng Wang, Srikanth Kotapati, Guodong Chen, Sayumi Yamazoe, Anastasia Kosenko, Gavin Dollinger, Tim Sproul, Arvind Rajpal, Pavel Strop   +25 more
doaj   +1 more source

Protein aggregation and immunogenicity of biotherapeutics

International Journal of Pharmaceutics, 2020
Recombinant proteins are the mainstay of biopharmaceuticals. A key challenge in the manufacturing and formulation of protein biologic products is the tendency for the active pharmaceutical ingredients to aggregate, resulting in irreversible drug loss, and an increase in immunogenicity risk.
Ngoc B, Pham, Wilson S, Meng
openaire   +3 more sources